ライフサイエンスコーパス: remit

1 bit subthreshold symptoms, or go on to fully remit.

2 Unfortunately, most patients fail to remit.

3 e, and Hispanic patients were more likely to remit.

4 ileptogenesis with spontaneous seizures that remit.

5 hat could become chronic even after symptoms remit.

6 g IC to LNs, suggesting a broader functional remit.

7 istory and were present even among those who remitted.

8 , 1.07-7.71]) compared with those whose ADHD remitted.

9 We prospectively recruited 20 relapsing-remitting, 15 secondary progressive multiple sclerosis p

10 re present in 16% of patients with relapsing-remitting, 16% of patients with progressive, and 12% of

11 ) had multiple sclerosis [94 (57%) relapsing-remitting, 25 (15%) secondary progressive], 45 (27%) rem

12 ols and 122 patients comprising 58 relapsing-remitting, 28 primary progressive and 36 secondary progr

13 clinically isolated syndrome, 198 relapsing remitting, 39 secondary progressive, 31 primary progress

14 Ten of 11 patients remitted (50% reduction in 24-item Hamilton Depression R

15 ncluded 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive) and 15 he

16 e rs2242446 C/C genotype were more likely to remit (73.1%) than those with either the C/T (51.8%) or

17 nically isolated syndrome, and 416 relapsing-remitting, 84 secondary progressive, and 73 primary prog

18 ent group, even in patients whose depression remitted acutely according to clinical measures.

19 D group showed under-activation, whereas the remitted ADHD group did not differ significantly from th

20 cording period, spontaneous seizure episodes remit after approximately 4 weeks.

21 adults followed since childhood, contrasting remitted against persistent ADHD.

22 arge vessels (MaxBTP) in comparison with the remitted and control groups.

23 n and Anxiety, including 2,292 patients with remitted and current diagnoses of depressive or anxiety

24 tom severity, a distinction was made between remitted and persistent patients.

25 hildren, while this group consists of future remitting and persistent individuals.

26 ting brain and spinal cord in both relapsing-remitting and progressive forms of MS and may be benefic

27 Individuals suffering from relapsing-remitting and secondary progressive MS had significantly

28 spinal cord of patients with early relapsing-remitting and secondary progressive multiple sclerosis;

29 ors and MS patients in the initial relapsing-remitting and subsequent secondary-progressive stage.

30 he subpial surfaces for those with relapsing-remitting and the central canal CSF surface in progressi

31 t remission criteria, 10.0% (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met

32 After treatment, 16 PTSD patients were remitted, and 23 had persistent PTSD based on PTSD diagn

33 ng evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis an

34 audal putamen functional connectivity in the remitted anorexia nervosa group compared with the contro

35 astant response in the control group and the remitted anorexia nervosa group, with an increase and a

36 on harm avoidance among participants in the remitted anorexia nervosa group.

37 olescents whose childhood ADHD symptoms have remitted are indistinguishable from neurotypical individ

38 atment failure (having neither responded nor remitted at the posttreatment assessment).

39 Behcet disease is a chronic, relapsing-remitting autoinflammatory syndrome with a strong HLA-B*

40 Results showed that persons with remitted (B=-52.6) and current (B=-60.8) depressive or a

41 h M. amphoriforme manifesting as a relapsing-remitting bacterial load, interspersed by periods when t

42 a broad cognitive dysfunction in affectively remitted BD patients.

43 in treatment-resistant depression (TRD) and remitted BD.

44 Affect was assessed pre and post scan in remitted Bipolar Disorder (n = 27) and age/gender-matche

45 unstructured peer support for patients with remitted bipolar disorder.

46 pletion led to reward-processing deficits in remitted bulimia nervosa, the purpose of this study was

47 ehavioral, and neural responses directly, 17 remitted bulimic (rBN) and 21 healthy individuals (HC) r

48 er fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation.

49 to suggest that even if distress appears to remit by adulthood, heightened risk of cardiometabolic d

50 llergic inflammation and that the disease is remitted by disrupting inflammatory and T-helper type 2

51 ), offspring with an episode of MDD that had remitted by follow-up (n = 4), and offspring with missin

52 .16-1.17) and 2.28 (2.25-2.32) times as many remitted cases at the end of the second year.

53 onally characterized by an initial relapsing-remitting clinical course and focal inflammatory lesions

54 The case is presented due to the relapsing-remitting clinical course of the disease that resulted i

55 y finding that both drugs increased the time remitted compared with placebo.

56 Over 9 mo, these mice exhibited a relapsing-remitting course of hind-limb clasping with the developm

57 Despite varying prior severity of relapsing-remitting course, all participants experienced unexpecte

58 terized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains la

59 me and, in most people, runs a relapsing and remitting course.

60 hy (n = 2100), high-risk healthy (n = 2023), remitted depressed (n = 401) and currently depressed chi

61 Remitted depressed (n=48) and healthy volunteers (n=48)

62 in how low-risk healthy, high-risk healthy, remitted depressed and currently depressed children perf

63 rently depressed individuals, 25 unmedicated remitted depressed individuals, and 30 individuals at hi

64 putatively at-risk for developing dementia- remitted depression (MDD), non-amnestic MCI (naMCI), MDD

65 tients with depression (n=25), patients with remitted depression (n=24) and community controls (n=25)

66 f nicotine dependence among individuals with remitted depression (rMDD).

67 Furthermore, studies of remitted depression suggest network-wide hyporeactivity

68 a neuroinflammatory disease with a relapsing-remitting disease course at early stages, distinct lesio

69 progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2-weighted

70 s more common in younger patients, relapsing-remitting disease course, and after a smaller change in

71 system, and take a chronic or relapsing and remitting disease course.

72 ed that pEVs induced a spontaneous relapsing-remitting disease phenotype in MOG(35-55)-immunized C57B

73 ecause atopic dermatitis (AD) is a relapsing remitting disease, assessing long-term control is import

74 o was observed in MS patients with relapsing-remitting disease.

75 younger patients and patients with relapsing-remitting disease.

76 at they have a role in chronic relapsing and remitting diseases of both barrier and non-barrier tissu

77 t relapse in a SJL animal model of relapsing-remitting EAE abrogated clinical disease, inflammation,

78 RO group) and chronic disease with relapsing-remitting episodes (C-RELAP group).

79 While some FEPs remain remitted even without medication, antipsychotic disconti

80 ive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomyelitis (EAE

81 lly, could suppress progression of relapsing-remitting experimental autoimmune encephalomyelitis (EAE

82 le of IL-11 in the exacerbation of relapsing-remitting experimental autoimmune encephalomyelitis (RRE

83 effective in three patients, and one patient remitted following rituximab treatment.

84 ine personality disorder were more likely to remit for a period of 2 years and for a period of 4 year

85 010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syndrome) wit

86 evitably the role of executive nurses, whose remit frequently includes responsibility for quality and

87 ADHD symptoms and explain why some children remit from ADHD, whereas others persist.

88 y breathing load paradigm, we compared women remitted from BN (RBN; n = 24; to reduce the confounding

89 and two vulnerable populations: individuals remitted from depression and otherwise healthy individua

90 o spent more than 6 months in an institution remitted from markedly higher rates at ages 6 years (p=0

91 the classifier that differentiates relapsing-remitting from progressive MS achieved a validated AUROC

92 set and 4 weeks associated with relapsing or remitting HCMV viremia.

93 autoimmunity, type 1 diabetes and relapsing-remitting immune-mediated demyelination.

94 Common, mild disorders often remit in young adulthood, but more severe disorders can

95 Weakness had completely remitted in 20% of patients in the functional limb weakn

96 type 2 diabetes at baseline, type 2 diabetes remitted in 66 of 88 patients (75%) at 2 years, in 54 of

97 Depression remitted in just over one-half of subjects following ser

98 cies responsible for a chronic relapsing and remitting infection in PAD patients in the United Kingdo

99 ltiple sclerosis (MS) is a chronic relapsing-remitting inflammatory disease of the central nervous sy

100 wel disease (IBD) is a chronic relapsing and remitting inflammatory disease of the gastrointestinal t

101 Crohn's disease is a relapsing and remitting inflammatory disorder with a variable clinical

102 The group's remit is to provide expert guidance for the long-term ma

103 We analyzed data from 80 older adults with remitted major depression (36 with mild cognitive impair

104 Patients with remitted major depressive disorder (MDD) were previously

105 from healthy controls and from patients with remitted major depressive disorder on antidepressants.

106 progressive disease compared with relapsing-remitting males (RRMS) and female MS subjects, with incr

107 f how and why recurrent, unprovoked seizures remit may further our understanding and treatment of epi

108 jects were divided into current MDD (N=882), remitted MDD (N=635) and control (N=331) groups.

109 A total of 63 medication-free remitted MDD (rMDD) patients (33 melancholic and 30 nonm

110 ndividuals with MDD, and 30 individuals with remitted MDD (rMDD) were included.

111 Older individuals with remitted MDD and naMCI did not have the same white or gr

112 5 psychotropic medication-free patients with remitted MDD and no relevant comorbidity.

113 This study investigated whether remitted melancholic MDD patients, who are at an elevate

114 dentified: never/infrequent, preschool-onset remitting, midchildhood-onset remitting, school age-onse

115 lapses and remissions in the SJL/J-relapsing-remitting model of EAE, and could comparably assess the

116 Using a relapsing-remitting model of EAE, here we demonstrate that when ap

117 proves the functional outcome in a relapsing/remitting model of experimental autoimmune encephalomyel

118 secondary progressive MS than with relapsing-remitting MS (3.6 lesions/year +/- 4.2 vs 1.1 lesions/ye

119 Participants were 31 patients with Relapsing-Remitting MS (mean age = 44.323 +/- 13.149; mean Expande

120 c imaging data in 46 patients with relapsing-remitting MS (median disease duration, 0.8 year) were an

121 diagnosis of either PPMS (n = 16), relapsing-remitting MS (n = 20), or benign MS (n = 20) and 40 age-

122 Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8) were incl

123 comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that of age- an

124 as a biomarker of regeneration in relapsing-remitting MS (RRMS) and whether disease-modifying therap

125 Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS

126 progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched healthy con

127 nically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) to SPMS.

128 structed from diffusion data in 58 relapsing-remitting MS (RRMS), 28 primary progressive MS (PPMS), 3

129 DSS scores <=3.5), all of whom had relapsing-remitting MS (RRMS), 3 (4%) had RRMS and EDSS scores >3.

130 luence T cell effector function in relapsing/remitting MS (RRMS), an autoimmune disease sustained by

131 (CSF) and blood from subjects with relapsing-remitting MS (RRMS; n = 12), other neurologic diseases (

132 019, 120 patients with MS (58 with relapsing-remitting MS [RRMS] and 62 with progressive MS [PMS]) an

133 ary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers, genetica

134 ers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive MS [SPMS],

135 cally isolated syndrome [CIS], 196 relapsing-remitting MS [RRMS], 34 progressive MS [PMS]), and 82 co

136 d Methods Twenty participants with relapsing-remitting MS and 13 with secondary progressive MS, along

137 ospective study, 326 patients with relapsing-remitting MS and 163 patients with progressive MS, 61 pa

138 Twenty-five patients with relapsing-remitting MS and 20 healthy control subjects underwent a

139 ty-seven consecutive patients with relapsing-remitting MS and 30 healthy, age-matched control partici

140 Twenty-six patients with relapsing-remitting MS and 32 healthy control subjects from four c

141 One hundred patients with relapsing-remitting MS and 50 healthy controls.

142 of clinically isolated syndrome or relapsing-remitting MS and a minimum of 7 years of prospective fol

143 were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based morphometry

144 xplain IPS and EF in patients with relapsing-remitting MS and confirms the central role of the thalam

145 l funiculi and gray matter (GM) in relapsing-remitting MS and GM atrophy in patients with progressive

146 nformed consent, six patients with relapsing-remitting MS and six healthy control subjects underwent

147 Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing primary-prog

148 countries examining patients with relapsing-remitting MS commencing DMTs (or clinical monitoring) be

149 t study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 patients with

150 atients with clinically definitive relapsing-remitting MS in comparison with healthy control subjects

151 ease course was classified as CIS, relapsing-remitting MS or secondary progressive MS (SPMS).

152 RRMS relaxing-remitting MS patients had lower WM white matter and GM g

153 In the present study, 15 relapsing-remitting MS patients receiving 1,000 mg of rituximab we

154 Ten relapsing-remitting MS patients were studied using the TSPO radiol

155 Relapsing-remitting MS patients who developed PML under NTZ therap

156 ependent cohort of untreated early relapsing-remitting MS patients.

157 Data on 201 pregnant women with relapsing-remitting MS were collected prospectively from January 1

158 2 studies) and diagnosed as having relapsing-remitting MS were eligible to participate in these studi

159 peripheral blood of patients with relapsing-remitting MS with a high disease score.

160 nically isolated syndrome [CIS] or relapsing-remitting MS) and were also compared to two other popula

161 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in

162 Among patients with relapsing-remitting MS, initial treatment with fingolimod, alemtuz

163 or identifying novel therapies for relapsing-remitting MS, it has proven to be less successful in ide

164 preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT,

165 e activity, among 99 patients with relapsing-remitting MS, who underwent blinded clinical and 3 T mag

166 l of IFN-beta for the treatment of relapsing-remitting MS.

167 sening of disease in patients with relapsing-remitting MS.

168 o satisfy traditional criteria for relapsing-remitting MS.

169 tic target for patients with early relapsing-remitting MS.

170 174 relapsing-remitting MS/CIS patients were included in this analysis

171 th clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disability Status

172 topoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an ongoing, mu

173 pinal fluid of patients with early relapsing-remitting multiple sclerosis (MS) and in active brain MS

174 ns and spinal cords of people with relapsing-remitting multiple sclerosis (MS) and progressive MS has

175 et, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of

176 e of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influenced by the o

177 Unexpectedly, progressive and relapsing-remitting multiple sclerosis (MS) patients have comparab

178 man autoimmune diseases, including relapsing-remitting multiple sclerosis (MS), in which increased IF

179 prevent progressive disability in relapsing-remitting multiple sclerosis (MS).

180 RI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

181 FTY720 is a treatment for relapsing remitting multiple sclerosis (MS).

182 inically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive mul

183 esion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-ab NMOSD pa

184 olimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lacking.

185 arization profile in patients with relapsing-remitting multiple sclerosis (RRMS) by high-dimensional

186 rebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have higher replacem

187 newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in

188 rculating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients and healthy

189 ly showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients exhibited e

190 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients who are sta

191 ples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients.

192 The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progres

193 rently marketed for the treatment of relapse remitting multiple sclerosis (RRMS), 2 offers several po

194 ging, or can be distinguished from relapsing-remitting multiple sclerosis (RRMS).

195 e has not been investigated in relapsing and remitting multiple sclerosis (RRMS).

196 cohort of neurologic autoimmunity (relapsing-remitting multiple sclerosis [MS] n = 110, HD n = 110; p

197 ring the clinical relapse of both, relapsing-remitting multiple sclerosis and neuromyelitis optica, a

198 with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary progressive m

199 the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the

200 cts on disability in patients with relapsing-remitting multiple sclerosis are maintained and cost eff

201 ients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres in Europe a

202 m propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six oth

203 e multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these reductions

204 gulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no efficacy

205 Analysis of pEVs from relapsing-remitting multiple sclerosis patients also identified fi

206 ellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 heathy cont

207 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using multiparamet

208 nd effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients.

209 Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence on diseas

210 Subjects with relapsing-remitting multiple sclerosis showed a greater predominan

211 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP,

212 nism underlying the progression of relapsing-remitting multiple sclerosis to secondary progressive mu

213 d interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years.

214 Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1

215 f CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neurological ex

216 with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple s

217 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of PML, were

218 rferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative

219 Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP showed effi

220 teria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one of the stu

221 ly prescribed for the treatment of relapsing-remitting multiple sclerosis, however, the mechanism of

222 led in this study, 24 patients had relapsing remitting multiple sclerosis, six had progressive multip

223 underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accumulation o

224 lt patients (aged >=18 years) with relapsing-remitting multiple sclerosis, with at least 6 years of f

225 mAb approved for the treatment of relapsing-remitting multiple sclerosis.

226 cts on annualised relapse rates in relapsing-remitting multiple sclerosis.

227 stration approved for treatment of relapsing-remitting multiple sclerosis.

228 prognostic factor in patients with relapsing-remitting multiple sclerosis.

229 cy of amiselimod in patients with relapsing- remitting multiple sclerosis.

230 a-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.

231 oral therapy for the treatment of relapsing remitting multiple sclerosis.

232 treatment of people suffering from relapsing-remitting multiple sclerosis.

233 imod is an effective treatment for relapsing-remitting multiple sclerosis.

234 f progressive patients compared to relapsing remitting multiple sclerosis.

235 al nervous system of patients with relapsing-remitting multiple sclerosis.

236 to adverse events in patients with relapsing-remitting multiple sclerosis?

237 iated with the atypical MDD subtype both for remitted (n = 144, odds ratio = 1.53, 95% confidence int

238 ssion and Anxiety with current (n = 1062) or remitted (n = 711) MDD and healthy control subjects (n =

239 hosis (n=12), compared with UHR subjects who remitted (n=41) and healthy controls (n=54).

240 multiple sclerosis patients with a relapsing remitting (n = 15) or a progressive (secondary, n = 15 o

241 metabolites are often considered within the remit of bacterial or plant research, but animals also c

242 laser physicists given this is outside their remit of expertise.

243 the Roundtable formed a focus team with the remit of identifying green chemistry and engineering imp

244 il now, this reaction has been primarily the remit of noble-metal catalysts, despite extensive work s

245 cer metabolism has evolved vastly beyond the remit of tumour proliferation and survival with the iden

246 ut only approximately half of these patients remit on SSRI therapy.

247 ifferences as a function of state (depressed/remitted) or number of previous episodes.

248 occurrence of spontaneous seizures naturally remits over time without any therapeutic intervention.

249 The remitted patients and combat controls did not differ on

250 response to negative pictures compared with remitted patients and combat controls.

251 ic patients could also be discriminated from remitted patients based on clinical characteristics (acc

252 Remitted patients with major depressive disorder (rMDD)

253 on of antidepressant users and proportion of remitted patients, and methodological characteristics di

254 sing were compared between the three groups (remitted patients, N=21; persistent patients, N=22; and

255 response to negative pictures compared with remitted patients.

256 .7% and 2.9 +/- 2.4%), compared to relapsing-remitting patients (1.6 +/- 2.1%, both P < 0.0001).

257 lesions in primary progressive than relapse-remitting patients (P < 0.001).

258 ected behaviour in the subgroup of relapsing remitting patients (rho = 0.74, P = 0.008).

259 white matter lesion enlargement in relapsing remitting patients and is associated with greater brain

260 urine samples from a cohort of 70 relapsing-remitting patients with MS who were followed for 2 years

261 higher in progressive compared to relapsing-remitting patients, with significant bilateral clusters

262 secondary progressive relative to relapsing-remitting patients.

263 by 31% (MLM) and 14% (Markov) for relapsing remitting patients.

264 lated clinical relapses during the relapsing-remitting phase of the disease.

265 e-modifying agents for its initial relapsing-remitting phase, these therapies show limited efficacy i

266 gest cross-sectional sample of patients with remitted psychotic depression (n = 86) collected to date

267 e structural brain networks in patients with remitted psychotic depression and brain-behavior relatio

268 We compared patients with remitted psychotic depression to healthy controls and fo

269 .55-1.57) and 5.73 (5.04-6.91) times as many remitted PTSD cases as non-SSCM conditions at the end of

270 ldiers that obtained remission (N = 21), non-remitted PTSD patients (N = 23), and trauma-exposed mili

271 area and ventral striatum in medication-free remitted recurrent depression patients (n = 36) versus h

272 Across adult life, CMH followed a dynamic remitting-relapsing course.

273 protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection.

274 e investigated this in people with relapsing-remitting (RR) and secondary progressive (SP) MS.

275 linically isolated syndrome (CIS), relapsing remitting (RR) and secondary progressive (SP) MS.

276 ting chronic-progressive (CP) versus relapse-remitting (RR) forms of the disease.

277 thylation in the CD4(+) T cells of relapsing-remitting (RR) MS patients compared to healthy controls

278 nalysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS patients and

279 of AHSCT for patients with active relapsing remitting (RRMS) and secondary progressive MS (SPMS).

280 nts, but not in a third cohorts of relapsing-remitting (RRMS) patients.

281 reschool-onset remitting, midchildhood-onset remitting, school age-onset persisting, late childhood-o

282 presents a case of a patient with relapsing-remitting severe BBE.

283 an treatments within one week from the onset remitted shortly.

284 stent MDD effects, regardless of episodes or remitted state, namely on proteomic measures related to

285 In the remitted state, only patients with BD showed impaired em

286 ted with medication use, acute compared with remitted status, first episode compared with recurrent s

287 : Adult participants (persistent ADHD, N=35; remit-ted ADHD, N=47; never affected, N=99) were scanned

288 Among those who remitted, the mean decrease in HAM-D score was 24.7 poin

289 The project has evolved from its original remit to collect and integrate all data for a single spe

290 rheumatism often being viewed as a relapsing-remitting variant of RA.

291 Within this remit we address three key questions: Q1 Does light-depe

292 ntelligence with lifetime disorders that had remitted were attenuated compared with past-year disorde

293 se 2 (reported separately), patients who had remitted were randomly assigned to receive pharmacothera

294 Midchildhood-onset (4(1/2) years) remitting wheeze was associated with BDR (OR, 1.77; 95%

295 Preschool-onset (18 months) remitting wheeze was only associated with FEV1/FVC ratio

296 der and whose major depression had failed to remit with venlafaxine hydrochloride monotherapy, 91 rec

297 which mice develop spontaneous seizures that remit within 1 month.

298 rd of patients with chronic anterior uveitis remit within 5 years.

299 ovide insights into why spontaneous seizures remit without anticonvulsant treatment.

300 epilepsy with recurrent, unprovoked seizures remitting without any intervention.